Studies in the role of HSP90 in cancer have gone from the first Phase I trials of 17-AAG to the discovery and synthetization of HSP90 inhibitors, such as ganetespib and luminespib, that are being researched today. The gene discussed is HSP90AB1; the disease is cancer.